Benedetta Massetto Selected Research

sofosbuvir drug combination ledipasvir

1/2022	Ledipasvir-sofosbuvir in Adolescents With Chronic Hepatitis C and Hematological Malignancies Undergoing Chemotherapy.
1/2022	Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment.
1/2020	Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C.
1/2019	Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
12/2018	Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
1/2018	Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection.
7/2017	Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
1/2017	Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial.
1/2017	The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Benedetta Massetto Research Topics

Disease

24	Infections 01/2022 - 04/2014
10	Chronic Hepatitis C 01/2022 - 07/2014
10	Chronic Hepatitis B 01/2018 - 09/2007
8	Fibrosis (Cirrhosis) 01/2019 - 07/2014
4	Headache (Headaches) 01/2019 - 11/2016
3	Nasopharyngitis 01/2018 - 11/2016
2	Hepatitis B 01/2022 - 01/2017
2	Hepatitis C 01/2018 - 09/2015
2	Respiratory Tract Infections (Respiratory Tract Infection) 11/2016 - 11/2016
1	Neoplasms (Cancer) 01/2022
1	Leukemia 01/2022
1	Liver Diseases (Liver Disease) 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2022
1	Fatigue 01/2019
1	Chronic Hepatitis (Chronic Active Hepatitis) 01/2019
1	Breast Neoplasms (Breast Cancer) 12/2018
1	Disease Progression 07/2017
1	Liver Neoplasms (Liver Cancer) 07/2017
1	Syncope (Fainting) 01/2017
1	Pulmonary Embolism 01/2017
1	Persistent Infection 01/2016
1	Coinfection 03/2015
1	Lipodystrophy 08/2003
1	Peripheral Nervous System Diseases (PNS Diseases) 12/2002

Drug/Important Bio-Agent (IBA)

15	Ribavirin (Virazole)FDA LinkGeneric 01/2022 - 07/2014
15	SofosbuvirIBA 01/2020 - 03/2015
9	sofosbuvir drug combination ledipasvirIBA 01/2022 - 01/2017
8	Antiviral Agents (Antivirals)IBA 01/2020 - 01/2016
6	Tenofovir (Viread)FDA Link 01/2019 - 04/2014
6	ledipasvirIBA 01/2019 - 07/2014
6	Hepatitis B e AntigensIBA 01/2019 - 09/2007
4	InterferonsIBA 01/2022 - 09/2007
3	vesatolimodIBA 01/2018 - 01/2015
3	Lamivudine (Epivir)FDA Link 01/2017 - 09/2007
2	VaccinesIBA 01/2019 - 01/2016
2	Peptides (Polypeptides)IBA 01/2019 - 12/2018
2	Proteins (Proteins, Gene)FDA Link 12/2018 - 07/2014
2	CreatinineIBA 01/2017 - 11/2016
2	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 11/2016
2	Emtricitabine (Emtriva)FDA Link 01/2017 - 04/2014
2	tenofovir alafenamideIBA 11/2016 - 11/2016
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2016 - 12/2014
1	AntigensIBA 01/2019
1	Interleukin-2 (IL2)IBA 01/2019
1	Interferon-gamma (Interferon, gamma)IBA 01/2019
1	ProteomeIBA 01/2019
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019
1	Cytochrome P-450 CYP3AIBA 12/2018
1	Cytochrome P-450 CYP2C9IBA 12/2018
1	AnionsIBA 12/2018
1	Rifampin (Rifampicin)FDA LinkGeneric 12/2018
1	TabletsIBA 12/2018
1	XenobioticsIBA 12/2018
1	Cytochrome P-450 CYP1A2 (CYP1A2)IBA 12/2018
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 12/2018
1	NucleotidesIBA 01/2018
1	lipoarabinomannan (LAM)IBA 01/2017
1	RacivirIBA 01/2017
1	Alanine Transaminase (SGPT)IBA 11/2016
1	Toll-Like Receptor 7IBA 01/2015
1	tegobuvirIBA 07/2014
1	NucleosidesIBA 07/2014
1	GS-9451IBA 07/2014
1	Protease Inhibitors (Protease Inhibitor)IBA 07/2014

Therapy/Procedure

4	Therapeutics 01/2020 - 02/2013
1	Drug Therapy (Chemotherapy) 01/2022
1	Maintenance Chemotherapy 01/2022
1	Aftercare (After-Treatment) 07/2017
1	Retreatment 09/2007
1	Art Therapy 08/2003
1	Highly Active Antiretroviral Therapy (HAART) 12/2002